Genmab A (GMAB) Non-Current Deffered Revenue (2023 - 2026)

Genmab A's Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $88.0 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 25.71% year-over-year to $88.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.0 million (up 25.71% YoY) and the FY2025 annual result came in at $95.0 million, up 41.79% from the prior year.
• Non-Current Deffered Revenue was $88.0 million for Q1 2026 at Genmab A, down from $95.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $95.0 million in Q4 2025 and bottomed at $67.0 million in Q4 2024.
• A 4-year average of $75.0 million and a median of $70.0 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue dropped 5.63% — and 2025, when it surged 41.79%.
• Genmab A's Non-Current Deffered Revenue stood at $71.0 million in 2023, then declined by 5.63% to $67.0 million in 2024, then surged by 41.79% to $95.0 million in 2025, then declined by 7.37% to $88.0 million in 2026.
• Business Quant data shows GMAB's Non-Current Deffered Revenue at $88.0 million in Q1 2026, $95.0 million in Q4 2025, and $67.0 million in Q3 2025.